Understanding the impact of climate change on mental health from a Canadian perspective: a scoping reviewl; Using health service data to understand unregulated toxic drug deaths in Alberta (2018â2023): an ecological study; Evolving student health priorities and school-based health-promoting interventions in Quebec, 2016â2025
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between May 1 and 31. 2026. The next update is scheduled for June 2026.
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to March 31, 2026. The next update of data is scheduled for early April 2026.
Content: Announcement: Breast implant recall subscription; 2025 AR data; Safety brief: Vitamin B6 health products and peripheral neuropathy.
Adherence to Lower-Risk Cannabis Use Guidelines among Canadian college students: a regression analysis; Concurrent mental health and substance use disorders among Canadian adults during the COVID-19 pandemic: a population-based study; Chronic disease and social isolation among Canadians: evidence from the 2022 Mental Health and Access to Care Survey
Adherence to Lower-Risk Cannabis Use Guidelines among Canadian college students: a regression analysis; Concurrent mental health and substance use disorders among Canadian adults during the COVID-19 pandemic: a population-based study; Chronic disease and social isolation among Canadians: evidence from the 2022 Mental Health and Access to Care Survey
The Committee to Advise on Tropical Medicine and Travel (CATMAT) provides the Public Health Agency of Canada (PHAC) with ongoing and timely medical, scientific, and public health advice relating to tropical infectious disease and health risks associated with international travel.
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between April 1 and 30, 2026. The next update is scheduled for July 2026.
Content: Safety brief: Diosmin or diosmin in combination with hesperidin; Lunsumio / Lunsumio SC: Authorization with conditions
The data presented in the Canada Vigilance Adverse Reaction Online Database has been updated and now includes information received by Health Canada up to January 31, 2026. The next update of data is scheduled for early June 2026.
